Skip to main content
Premium Trial:

Request an Annual Quote

Hyseq Names Chief Financial Officer

NEW YORK, April 25 – Hyseq said Wednesday it appointed Peter Garcia as chief financial officer.

“This is an important period for Hyseq as we are adding key players to the team and gathering momentum heading into the next phase of the company's growth," CEO Ted Love said in a statement.

The company was not immediately available to discuss whether Garcia was replacing someone or filling a new position.

Garcia was previously a CFO at other emerging life science companies, including Novacept, IntraBiotics Pharmaceuticals, and Dendreon.

Hyseq, a maker of gene-based products and biochips based in Sunnyvale, Calif., is currently working to establish a viable business. The company, which in February received a $20 million line of credit from its chairman, George Rathmann, to shore up its dwindling cash reserves, is gearing up to prepare for clinical trials for a number of its products.

The company is also in the process of considering seeking a new partner with whom to commercialize its biochip technology. A 1997 deal with Applied Biosystems to commercialize the biochips has not yet resulted in any commercial product.

The company is scheduled to report its first quarter earnings on Thursday before the market opens.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.